A drug that targets the cell surface receptors that play an important role in many types of cancer can bring about significant tumor regression in breast cancer after only six weeks of use.
Cancer researchers said that the work demonstrated for the first time that the tyrosine kinase inhibitor lapatinib could decrease tumor-causing breast cancer stem cells in the primary breast cancers of women receiving neoadjuvant treatment.
...
Post new comment